Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1970 1
1980 1
1985 1
1986 2
1987 1
1992 1
1994 2
1998 1
1999 1
2001 4
2002 6
2003 6
2004 4
2005 6
2006 8
2007 5
2008 8
2009 4
2010 5
2011 9
2012 12
2013 13
2014 8
2015 8
2016 8
2017 8
2018 11
2019 9
2020 15
2021 9
2022 9
2023 11
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

166 results

Results by year

Filters applied: . Clear all
Page 1
Edoxaban versus warfarin in patients with atrial fibrillation.
Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL, Waldo AL, Ezekowitz MD, Weitz JI, Špinar J, Ruzyllo W, Ruda M, Koretsune Y, Betcher J, Shi M, Grip LT, Patel SP, Patel I, Hanyok JJ, Mercuri M, Antman EM; ENGAGE AF-TIMI 48 Investigators. Giugliano RP, et al. N Engl J Med. 2013 Nov 28;369(22):2093-104. doi: 10.1056/NEJMoa1310907. Epub 2013 Nov 19. N Engl J Med. 2013. PMID: 24251359 Free article. Clinical Trial.
BACKGROUND: Edoxaban is a direct oral factor Xa inhibitor with proven antithrombotic effects. The long-term efficacy and safety of edoxaban as compared with warfarin in patients with atrial fibrillation is not known. ...
BACKGROUND: Edoxaban is a direct oral factor Xa inhibitor with proven antithrombotic effects. The long-term efficacy and safety of ed …
Donor Clonal Hematopoiesis and Recipient Outcomes After Transplantation.
Gibson CJ, Kim HT, Zhao L, Murdock HM, Hambley B, Ogata A, Madero-Marroquin R, Wang S, Green L, Fleharty M, Dougan T, Cheng CA, Blumenstiel B, Cibulskis C, Tsuji J, Duran M, Gocke CD, Antin JH, Nikiforow S, DeZern AE, Chen YB, Ho VT, Jones RJ, Lennon NJ, Walt DR, Ritz J, Soiffer RJ, Gondek LP, Lindsley RC. Gibson CJ, et al. J Clin Oncol. 2022 Jan 10;40(2):189-201. doi: 10.1200/JCO.21.02286. Epub 2021 Nov 18. J Clin Oncol. 2022. PMID: 34793200 Free PMC article.
PATIENTS AND METHODS: We performed targeted error-corrected sequencing on samples from 1,727 donors age 40 years or older and assessed the effect of donor CH on recipient clinical outcomes. We measured long-term engraftment of 102 donor clones and cytokine levels in 256 re …
PATIENTS AND METHODS: We performed targeted error-corrected sequencing on samples from 1,727 donors age 40 years or older and assessed the e …
Liraglutide and Renal Outcomes in Type 2 Diabetes.
Mann JFE, Ørsted DD, Brown-Frandsen K, Marso SP, Poulter NR, Rasmussen S, Tornøe K, Zinman B, Buse JB; LEADER Steering Committee and Investigators. Mann JFE, et al. N Engl J Med. 2017 Aug 31;377(9):839-848. doi: 10.1056/NEJMoa1616011. N Engl J Med. 2017. PMID: 28854085 Free article. Clinical Trial.
BACKGROUND: In a randomized, controlled trial that compared liraglutide, a glucagon-like peptide 1 analogue, with placebo in patients with type 2 diabetes and high cardiovascular risk who were receiving usual care, we found that liraglutide resulted in lower risks of the primary …
BACKGROUND: In a randomized, controlled trial that compared liraglutide, a glucagon-like peptide 1 analogue, with placebo in patients with t …
Clinical Pharmacokinetics and Pharmacodynamics of CSL112.
Ortega-Paz L, Giordano S, Capodanno D, Mehran R, Gibson CM, Angiolillo DJ. Ortega-Paz L, et al. Among authors: gibson cm. Clin Pharmacokinet. 2023 Apr;62(4):541-558. doi: 10.1007/s40262-023-01224-8. Epub 2023 Mar 16. Clin Pharmacokinet. 2023. PMID: 36928983 Free PMC article. Review.
For decades, high-density lipoprotein (HDL) has been among the therapeutic targets for long-term prevention after an ischemic event. However, early trials focusing on increasing HDL circulating levels showed no improvement in clinical outcomes. ...
For decades, high-density lipoprotein (HDL) has been among the therapeutic targets for long-term prevention after an ischemic event. …
Clonal hematopoiesis in older patients with breast cancer receiving chemotherapy.
Mayerhofer C, Sedrak MS, Hopkins JO, Li T, Tayob N, Faggen MG, Sinclair NF, Chen WY, Parsons HA, Mayer EL, Lange PB, Basta AS, Perilla-Glen A, Lederman RI, Wong AR, Tiwari A, McAllister SS, Mittendorf EA, Gibson CJ, Burstein HJ, Kim AS, Freedman RA, Miller PG. Mayerhofer C, et al. Among authors: gibson cj. J Natl Cancer Inst. 2023 Aug 8;115(8):981-988. doi: 10.1093/jnci/djad065. J Natl Cancer Inst. 2023. PMID: 37042724 Free PMC article.
Though chemotherapy is a known risk factor for developing CH, how myelosuppressive therapies affect the short-term dynamics of CH remains incompletely understood. Most studies have been limited by retrospective design, heterogeneous patient populations, varied techniques t …
Though chemotherapy is a known risk factor for developing CH, how myelosuppressive therapies affect the short-term dynamics of CH rem …
Vascular anomalies: special considerations in children.
Gibson CR, Barnacle AM. Gibson CR, et al. CVIR Endovasc. 2020 Nov 22;3(1):60. doi: 10.1186/s42155-020-00153-y. CVIR Endovasc. 2020. PMID: 32886264 Free PMC article. Review.
Although many of the principles of sclerotherapy and embolisation are the same in adult and paediatric practice, there are some key differences in the approach for children, including some longer term thinking about managing these chronic diseases and their impact on a gro …
Although many of the principles of sclerotherapy and embolisation are the same in adult and paediatric practice, there are some key differen …
Bridging Treatment Implementation Gaps in Patients With Heart Failure: JACC Focus Seminar 2/3.
Jalloh MB, Averbuch T, Kulkarni P, Granger CB, Januzzi JL, Zannad F, Yeh RW, Yancy CW, Fonarow GC, Breathett K, Gibson CM, Van Spall HGC. Jalloh MB, et al. Among authors: gibson cm. J Am Coll Cardiol. 2023 Aug 8;82(6):544-558. doi: 10.1016/j.jacc.2023.05.050. J Am Coll Cardiol. 2023. PMID: 37532425 Free article. Review.
We propose an evidence-to-care conceptual model that could foster the simultaneous generation of evidence and long-term implementation. By adopting principles of implementation science, policymakers, researchers, and clinicians can help reduce the burden of HF on patients …
We propose an evidence-to-care conceptual model that could foster the simultaneous generation of evidence and long-term implementatio …
Thrombolytics and myocardial infarction.
Kunadian V, Gibson CM. Kunadian V, et al. Among authors: gibson cm. Cardiovasc Ther. 2012 Apr;30(2):e81-8. doi: 10.1111/j.1755-5922.2010.00239.x. Epub 2010 Nov 11. Cardiovasc Ther. 2012. PMID: 21070617 Free article. Review.
Following a series of investigations, streptokinase was discovered and demonstrated to be beneficial for the treatment of patients with acute myocardial infarction in terms of reducing short- and long-term mortality. Newer agents including tissue plasminogen activators suc …
Following a series of investigations, streptokinase was discovered and demonstrated to be beneficial for the treatment of patients with acut …
Liraglutide protects β-cells in novel human islet spheroid models of type 1 diabetes.
Yesildag B, Mir-Coll J, Neelakandhan A, Gibson CB, Perdue NR, Rufer C, Karsai M, Biernath A, Forschler F, Jin PW, Misun PM, Title A, Hierlemann A, Kreiner FF, Wesley JD, von Herrath MG. Yesildag B, et al. Among authors: gibson cb. Clin Immunol. 2022 Nov;244:109118. doi: 10.1016/j.clim.2022.109118. Epub 2022 Sep 6. Clin Immunol. 2022. PMID: 36084852
To enable accurate, high-throughput and longer-term studies of the immunopathogenesis of type 1 diabetes (T1D), we established three in-vitro islet-immune injury models by culturing spheroids derived from primary human islets with proinflammatory cytokines, activated perip …
To enable accurate, high-throughput and longer-term studies of the immunopathogenesis of type 1 diabetes (T1D), we established three …
Patient Adherence to Secondary Prevention Therapies After an Acute Coronary Syndrome: A Scoping Review.
Bahit MC, Korjian S, Daaboul Y, Baron S, Bhatt DL, Kalayci A, Chi G, Nara P, Shaunik A, Gibson CM. Bahit MC, et al. Among authors: gibson cm. Clin Ther. 2023 Nov;45(11):1119-1126. doi: 10.1016/j.clinthera.2023.08.011. Epub 2023 Sep 9. Clin Ther. 2023. PMID: 37690915 Free article. Review.
PURPOSE: Adherence to guideline-recommended, long-term secondary preventative therapies among patients with acute coronary syndrome (ACS) is fundamental to improving long-term outcomes. ...IMPLICATIONS: Patient nonadherence to guideline-recommended long-term …
PURPOSE: Adherence to guideline-recommended, long-term secondary preventative therapies among patients with acute coronary syndrome ( …
166 results